Q-omics provides the consensus-scored RPS10P21 profile across patient tissues and cancer cell-line models. RPS10P21 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS10P21 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RPS10P21 RNA expression shows 6,390 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, THCA, and STAD as cancer lineages where RPS10P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS10P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS10P21 survival associations across molecular data types. RPS10P21 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS10P21 RNA expression–survival associations across cancer types. High RPS10P21 expression shows unfavorable associations in KIRC, UVM, SKCM, THCA and ESCA, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS10P21 RNA expression.
This table summarizes RPS10P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS10P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS10P21 shows lower tumor expression in THCA and BRCA. The THCA box plot shows higher RPS10P21 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .001).
This table shows molecular features associated with RPS10P21 in patient tissues and cancer cell lines. In patient samples, RPS10P21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
